ZimVie Reports Second Quarter 2025 Financial Results

Core Viewpoint - ZimVie Inc. reported its financial results for the second quarter of 2025, showing a slight decline in net sales but an improvement in net loss compared to the previous year. The company is also in the process of being acquired by an affiliate of ARCHIMED for $19.00 per share, which will take ZimVie private and remove its shares from NASDAQ trading. Financial Performance - Net sales for Q2 2025 were $116.7 million, a decrease of 0.1% on a reported basis and 2.1% in constant currency compared to Q2 2024 [2][3] - The net loss for Q2 2025 was $(3.8) million, an improvement of $5.7 million from a net loss of $(9.6) million in Q2 2024 [3][9] - The net loss margin for Q2 2025 was (3.3%), improving by 490 basis points from (8.2%) in Q2 2024 [3][4] - Adjusted net income for Q2 2025 was $7.2 million, an increase of $3.6 million from Q2 2024 [3][4] Earnings Per Share - Basic and diluted EPS for Q2 2025 were $(0.14), while adjusted diluted EPS was $0.26 [4][9] Adjusted EBITDA - Adjusted EBITDA for Q2 2025 was $17.5 million, representing 15.0% of net sales, an increase of $1.6 million or 150 basis points from Q2 2024 [4][9] Acquisition Details - On July 21, 2025, ZimVie announced a definitive agreement to be acquired by an affiliate of ARCHIMED for $19.00 in cash per share [6][7] - The transaction is expected to close by year-end 2025, pending stockholder approval and regulatory approvals [7][9] Company Overview - ZimVie is a global leader in the dental implant market, focusing on developing and delivering products for dental tooth replacement and restoration [9][10]